Literature DB >> 21619951

Bisphosphonates do not alter the rate of secondary mineralization.

Robyn K Fuchs1, Meghan E Faillace, Matt R Allen, Roger J Phipps, Lisa M Miller, David B Burr.   

Abstract

Bisphosphonates function to reduce bone turnover, which consequently increases the mean degree of tissue mineralization at an organ level. However, it is not clear if bisphosphonates alter the length of time required for an individual bone-modeling unit (BMU) to fully mineralize. We have recently demonstrated that it takes ~350 days (d) for normal, untreated cortical bone to fully mineralize. The aim of this study was to determine the rate at which newly formed trabecular BMUs become fully mineralized in rabbits treated for up to 414 d with clinical doses of either risedronate (RIS) or alendronate (ALN). Thirty-six, 4-month old virgin female New Zealand white rabbits were allocated to RIS (n=12; 2.4 μg/kg body weight), ALN (n=12; 2.4 μg/kg body weight), or volume-matched saline controls (CON; n=12). Fluorochrome labels were administered at specific time intervals to quantify the rate and level of mineralization of trabecular bone from the femoral neck (FN) by Fourier transform infrared microspectroscopy (FTIRM). The organic (collagen) and inorganic (phosphate and carbonate) IR spectral characteristics of trabecular bone from undecalcified 4 micron thick tissue sections were quantified from fluorescently labels regions that had mineralized for 1, 8, 18, 35, 70, 105, 140, 210, 280, and 385 d (4 rabbits per time point and treatment group). All groups exhibited a rapid increase in mineralization over the first 18 days, the period of primary mineralization, with no significant differences between treatments. Mineralization continued to increase, at a slower rate up, to 385 days (secondary mineralization), and was not different among treatments. There were no significant differences between treatments for the rate of mineralization within an individual BMU; however, ALN and RIS both increased global tissue mineralization as demonstrated by areal bone mineral density from DXA. We conclude that increases in tissue mineralization that occur following a period of bisphosphonate treatment is a function of the suppressed rate of remodeling that allows for a greater number of BMUs to obtain a greater degree of mineralization.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21619951     DOI: 10.1016/j.bone.2011.05.009

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  14 in total

Review 1.  Bone mineralization: from tissue to crystal in normal and pathological contexts.

Authors:  Y Bala; D Farlay; G Boivin
Journal:  Osteoporos Int       Date:  2012-12-11       Impact factor: 4.507

2.  Alendronate does not prevent long bone fragility in an inactive rat model.

Authors:  K Naruse; K Uchida; M Suto; K Miyagawa; A Kawata; K Urabe; M Takaso; M Itoman; Y Mikuni-Takagaki
Journal:  J Bone Miner Metab       Date:  2015-10-16       Impact factor: 2.626

3.  Effects of long-term alendronate treatment on postmenopausal osteoporosis bone material properties.

Authors:  N Hassler; S Gamsjaeger; B Hofstetter; W Brozek; K Klaushofer; E P Paschalis
Journal:  Osteoporos Int       Date:  2014-10-15       Impact factor: 4.507

Review 4.  Cellular Processes by Which Osteoblasts and Osteocytes Control Bone Mineral Deposition and Maturation Revealed by Stage-Specific EphrinB2 Knockdown.

Authors:  Martha Blank; Natalie A Sims
Journal:  Curr Osteoporos Rep       Date:  2019-10       Impact factor: 5.096

Review 5.  Long-term safety of antiresorptive treatment: bone material, matrix and mineralization aspects.

Authors:  Barbara M Misof; Nadja Fratzl-Zelman; Eleftherios P Paschalis; Paul Roschger; Klaus Klaushofer
Journal:  Bonekey Rep       Date:  2015-02-11

6.  Effects of 3 years treatment with once-yearly zoledronic acid on the kinetics of bone matrix maturation in osteoporotic patients.

Authors:  S Gamsjaeger; B Hofstetter; E Zwettler; R Recker; J A Gasser; E F Eriksen; K Klaushofer; E P Paschalis
Journal:  Osteoporos Int       Date:  2012-11-15       Impact factor: 4.507

7.  Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy.

Authors:  B Hofstetter; S Gamsjaeger; F Varga; H Dobnig; J J Stepan; H Petto; I Pavo; K Klaushofer; E P Paschalis
Journal:  Osteoporos Int       Date:  2014-07-19       Impact factor: 4.507

Review 8.  Cortical bone development, maintenance and porosity: genetic alterations in humans and mice influencing chondrocytes, osteoclasts, osteoblasts and osteocytes.

Authors:  Tsuyoshi Isojima; Natalie A Sims
Journal:  Cell Mol Life Sci       Date:  2021-07-01       Impact factor: 9.261

Review 9.  Bisphosphonates and bone quality.

Authors:  Michael Pazianas; Stefan van der Geest; Paul Miller
Journal:  Bonekey Rep       Date:  2014-05-07

10.  Effect of sequential treatments with alendronate, parathyroid hormone (1-34) and raloxifene on cortical bone mass and strength in ovariectomized rats.

Authors:  Sarah K Amugongo; Wei Yao; Junjing Jia; Weiwei Dai; Yu-An E Lay; Li Jiang; Danielle Harvey; Elizabeth A Zimmermann; Eric Schaible; Neil Dave; Robert O Ritchie; Donald B Kimmel; Nancy E Lane
Journal:  Bone       Date:  2014-07-10       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.